Managed Healthcare Executive

12/22/2025

What do the 2025 State of the Industry Survey results signal for leadership teams? Experts are weighing in on the findings that matter most. Shawn Gremminger, M.P.P., president and CEO of the National Alliance of Healthcare Purchaser Coalitions, noted:
“I was baffled and disappointed that market consolidation was fifth among concerns about U.S. health care in 2026…”

Discover what other leaders are saying about the year ahead and let us know which finding is most shocking to you! Access the Results Here: https://hubs.li/Q03YS1f80

12/20/2025

Happy Holidays from the Managed Healthcare Executive team!

We’re grateful for everyone in our community and the important work you do every day.

Wishing you peace, joy, and a wonderful year to come.

12/18/2025

The most-read stories by Managed Healthcare Executive®’s audience included coverage of a small peptide challenging the dominance of traditional biologics, new research into “forever chemicals” and the role of dermatologists in obesity.

The top stories out of the AAD annual meeting highlight how dermatology care is evolving.

12/18/2025

The results are in! Our 2025 State of the Industry Survey reveals what healthcare leaders identify as the biggest cost pressures, policy concerns and innovation opportunities shaping managed care in 2026.

Access the full findings now — do they match what you’re seeing as you define priorities moving forward? https://hubs.li/Q03YCX3r0

12/16/2025

Expiration of enhanced ACA subsidies in 2026 could lead to a 114% premium increase, affecting millions of Americans

Enrollment in Affordable Care Act health plans has soared because of enhanced subsidies enacted during the COVID-19 public health emergency. Democrats (and perhaps some moderate Republicans) want them continued. Republicans say they have better ideas about how to keep Americans in the individual mar...

12/11/2025

How IRA drug pricing could reshape PBMs’ negotiation power, health plan formularies, patient access and affordability

Medicare's first negotiated drug prices, effective January 2026, provide modest discounts, with limited savings for most beneficiaries and some unintended consequences.

12/10/2025

New drug approvals in dermatology in 2025 included a gene therapy for rare skin disorders and targeted treatments for two conditions.
https://hubs.li/Q03XH55S0

12/09/2025

CAR T-cell therapy revolutionizes treatment for aggressive blood cancers, but financial hurdles impact patient access

In this interview, George Eastwood, Executive Director of the Emily Whitehead Foundation and CAR T Vision steering committee member discusses barriers and strategies for expanding access to CAR T-cell therapy.

12/09/2025

Join us on January 13 for an in-depth look at what will shape the pharma market in the year ahead. Experts Luke Greenwalt, MBA (IQVIA), and Jeff Casberg, RPh, MS (IPD Analytics) will break down the MFN policy, DTC dynamics, GLP-1 demand, market forces, and key approvals to watch.
If you work in managed care, policy, market access, or health system leadership, this webinar will help you prepare for the challenges and opportunities coming in 2026.
Save your seat today! https://hubs.li/Q03XxMhZ0

12/09/2025

Lower for Longer: Lessons in Lipid Management

This K-Cast panelist reviewed findings from the Outcomes trial, where bempedoic acid reduced cardiovascular events by 13% in nearly 14,000 statin-intolerant patients over 4.9 years, with excellent tolerability.

Long-term data from PCSK9 inhibitor studies, such as the FOURIER trial, further reinforced sustained safety and efficacy over five to eight years.

The key takeaway: patients who start treatment earlier maintain cardiovascular protection benefits that late-starters can’t fully achieve, even with similar reductions.

Watch the episode to learn more: https://hubs.li/Q03XthKB0

12/04/2025

How far have we come in treating hemophilia with factor replacement therapy, and where are the gaps that remain?

In this K-Cast episode, experts provide a historical perspective on traditional factor replacement therapies, charting their development from early innovations to modern formulations. The discussion explores both the clinical successes that shaped standard care and the ongoing limitations (short half-life, infusion requirements, and inhibitor formation) that continue to challenge patients and clinicians alike.

12/02/2025

New research from Stanford Medicine links Epstein-Barr virus to Systemic Lupus Erythematosus, potentially rewriting what we know about this disease.

In lupus patients, latent Epstein-Barr virus can reprogram B cells and send the body’s immune response into overdrive, resulting in widespread inflammation.